• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

[Increasing combination possibilities for first-line treatment of metastatic clear cell renal cell carcinoma with nivolumab plus cabozantinib].

作者信息

Oing Christoph, Bokemeyer Carsten

机构信息

II. Medizinische Klinik & Poliklinik, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Deutschland.

Klinik für Onkologie, Hämatologie und Stammzelltransplantation mit Abteilung für Pneumologie und Mildred Scheel-Nachwuchszentrum HaTriCS4, Universitätsklinikum Eppendorf, Martinistraße 52, 20246 Hamburg, Deutschland.

出版信息

Onkologe (Berl). 2021;27(2):168-171. doi: 10.1007/s00761-020-00891-7. Epub 2021 Jan 5.

DOI:10.1007/s00761-020-00891-7
PMID:33424137
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7783494/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/37b3/7783494/91640e998021/761_2020_891_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/37b3/7783494/91640e998021/761_2020_891_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/37b3/7783494/91640e998021/761_2020_891_Fig1_HTML.jpg

相似文献

1
[Increasing combination possibilities for first-line treatment of metastatic clear cell renal cell carcinoma with nivolumab plus cabozantinib].[纳武单抗联合卡博替尼用于转移性透明细胞肾细胞癌一线治疗的联合可能性增加]
Onkologe (Berl). 2021;27(2):168-171. doi: 10.1007/s00761-020-00891-7. Epub 2021 Jan 5.
2
Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naïve Metastatic Clear-Cell Renal Cell Carcinoma.更新的欧洲泌尿外科学会肾癌指南：纳武利尤单抗联合卡博替尼加入免疫检查点抑制联合治疗用于治疗初治转移性透明细胞肾细胞癌。
Eur Urol. 2021 Mar;79(3):339-342. doi: 10.1016/j.eururo.2020.12.005. Epub 2020 Dec 24.
3
Efficacy of Cabozantinib in Metastatic Papillary Renal Cell Carcinoma Following Ineffective Treatment With Initial Therapy of Nivolumab and Ipilimumab.卡博替尼治疗纳武利尤单抗和伊匹单抗初始治疗失败的转移性乳头状肾细胞癌的疗效。
In Vivo. 2021 May-Jun;35(3):1743-1747. doi: 10.21873/invivo.12433.
4
Real-world outcomes of nivolumab and cabozantinib in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.纳武利尤单抗和卡博替尼治疗转移性肾细胞癌的真实世界结局：来自国际转移性肾细胞癌数据库联盟的结果。
Curr Oncol. 2019 Apr;26(2):e175-e179. doi: 10.3747/co.26.4595. Epub 2019 Apr 1.
5
Cost-Effectiveness Analysis of First-Line Nivolumab Plus Cabozantinib for Advanced Renal Cell Carcinoma in the United States.美国一线纳武利尤单抗联合卡博替尼治疗晚期肾细胞癌的成本效果分析。
Adv Ther. 2021 Dec;38(12):5662-5670. doi: 10.1007/s12325-021-01926-0. Epub 2021 Oct 18.
6
Cost-Effectiveness of Nivolumab Plus Cabozantinib Versus Sunitinib as a First-Line Treatment for Advanced Renal Cell Carcinoma in the United States.纳武单抗联合卡博替尼对比舒尼替尼作为美国晚期肾细胞癌一线治疗的成本效益
Front Pharmacol. 2021 Dec 13;12:736860. doi: 10.3389/fphar.2021.736860. eCollection 2021.
7
First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis.转移性肾细胞癌的一线系统治疗：系统评价和网络荟萃分析。
Eur Urol. 2018 Sep;74(3):309-321. doi: 10.1016/j.eururo.2018.03.036. Epub 2018 Apr 13.
8
First-line Immunotherapy-based Combinations for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis.一线免疫治疗联合方案治疗转移性肾细胞癌的系统评价和网络荟萃分析。
Eur Urol Oncol. 2021 Oct;4(5):755-765. doi: 10.1016/j.euo.2021.03.001. Epub 2021 Mar 20.
9
Nivolumab versus Cabozantinib: Comparing Overall Survival in Metastatic Renal Cell Carcinoma.纳武利尤单抗对比卡博替尼：转移性肾细胞癌总生存期的比较
PLoS One. 2016 Jun 6;11(6):e0155389. doi: 10.1371/journal.pone.0155389. eCollection 2016.
10
Cabozantinib real-world effectiveness in the first-through fourth-line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.卡博替尼在转移性肾细胞癌一线至四线治疗中的真实世界疗效：来自国际转移性肾细胞癌数据库联盟的结果。
Cancer Med. 2021 Feb;10(4):1212-1221. doi: 10.1002/cam4.3717. Epub 2021 Jan 18.

引用本文的文献

1
[Structural, procedural, and personnel requirements for provision of radiation oncology and radiation therapy services in Germany in 2023-a position paper of the German Society of Radiation Oncologists (DEGRO)].[2023年德国提供放射肿瘤学和放射治疗服务的结构、程序及人员要求——德国放射肿瘤学会（DEGRO）立场文件]
Strahlenther Onkol. 2023 Aug;199(8):697-705. doi: 10.1007/s00066-023-02105-6. Epub 2023 Jun 19.
2
First-line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta-analysis.一线治疗成人晚期肾细胞癌：系统评价和网络荟萃分析。
Cochrane Database Syst Rev. 2023 May 4;5(5):CD013798. doi: 10.1002/14651858.CD013798.pub2.

本文引用的文献

1
Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 Study.卡博替尼联合阿替利珠单抗治疗晚期肾细胞癌：来自 COSMIC-021 研究的结果。
J Clin Oncol. 2021 Nov 20;39(33):3725-3736. doi: 10.1200/JCO.21.00939. Epub 2021 Sep 7.
2
Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial.纳武利尤单抗联合伊匹单抗对比舒尼替尼用于晚期肾细胞癌患者的生存结局和独立应答评估：一项随机 3 期临床试验的 42 个月随访结果。
J Immunother Cancer. 2020 Jul;8(2). doi: 10.1136/jitc-2020-000891.
3
Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma.
JAVELIN肾101试验的最新疗效结果：一线阿维鲁单抗联合阿昔替尼与舒尼替尼治疗晚期肾细胞癌患者的对比
Ann Oncol. 2020 Aug;31(8):1030-1039. doi: 10.1016/j.annonc.2020.04.010. Epub 2020 Apr 25.
4
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial.纳武利尤单抗联合伊匹单抗对比舒尼替尼用于晚期肾细胞癌的一线治疗：来自一项随机、对照、III 期临床试验的疗效和安全性结果的扩展随访。
Lancet Oncol. 2019 Oct;20(10):1370-1385. doi: 10.1016/S1470-2045(19)30413-9. Epub 2019 Aug 16.
5
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.派姆单抗联合阿昔替尼对比舒尼替尼用于晚期肾细胞癌。
N Engl J Med. 2019 Mar 21;380(12):1116-1127. doi: 10.1056/NEJMoa1816714. Epub 2019 Feb 16.